PROLOR Won New US Patent Covering CTP Platform for Long-Acting Therapeutic Proteins

PROLOR Biotech, Inc.

today announced that it received a notice of allowance from the U.S. Patent and Trademark Office for a patent application covering the company's CTP platform, which has the potential to extend the duration of activity of therapeutic proteins.  The allowed claims cover manufacturing methods for CTP-modified compositions of a wide array of classes of therapeutic proteins, including hormones, high affinity protein ligands, proteins that induce or regulate an immune response, proteins involved with autocrine and paracrine activities, and mimetics of these therapeutic proteins, as well as other types of proteins. This new U.S. patent is expected to be issued in the next few months.